Education

Fellowship
Medicine/Infectious Disease, UCLA School of Medicine, 1996
Residency
Internal Medicine, UCLA School of Medicine, 1993
Internship
Internal Medicine, UCLA School of Medicine, 1991
Degree
MD, George Washington University School of Medicine, 1990

Medical Board Certifications

Infectious Disease
American Board of Internal Medicine, 1996
Internal Medicine
American Board of Internal Medicine, 1993

State License

G73936
  • About Me

    About Me

    Dr. Carlson is the medical director of the CARE Clinic and is responsible for the care of HIV infected adults, as well as the education of housestaff in HIV care at UCLA. She also sees both outpatients and inpatients with transplant related infections.

    Links

  • Locations

    UCLA CARE Clinic

    (primary location)
    Address
    1399 S. Roxbury Drive
    Suite 100
    Los Angeles, California 90035
    Phone
    310-557-2273
  • Education

    Medical Board Certifications

    Infectious Disease
    American Board of Internal Medicine, 1996
    Internal Medicine
    American Board of Internal Medicine, 1993

    Education

    Fellowship
    Medicine/Infectious Disease, UCLA School of Medicine, 1996
    Residency
    Internal Medicine, UCLA School of Medicine, 1993
    Internship
    Internal Medicine, UCLA School of Medicine, 1991
    Degree
    MD, George Washington University School of Medicine, 1990
  • Clinical Interests
    • AIDS
    • HIV
    • Transplant Infectious Diseases
  • Research

    Publications

    Selected Recent Publications

    1. Jabs DA, Gilpin AM, Min YI, et al. Studies of Ocular Complications of AIDS Research Group. HIV and CMV viral load and clinical outcomes in AIDS and CMV Retinitis patients: Monoclonal Antibody CMV Retinitis Trial. AIDS 2002;16:877-887.
    2. Kilby J, Lalezari J, Eron J, Carlson, M, et al. Safety, Plasma Pharmacokinetics And Antiviral Activity of Subcutaneous T-20, A Peptide Inhibitor Of gp41-Mediated Infusion, In HIV Infected Adults. AIDS Research Human Retroviruses 2002;18:685-693.
    3. Holbrook, Janet et al. Visual Loss in Patients with CMV Retinitis and AIDS before Widespread Availability of Highly Active Antiretroviral Therapy. Archives of Ophthalmology 2003;121:99-107.
    4. Lalezari J, Eron J, Carlson M, et al. A Phase II clinical study of the long –term safety and antiviral activity of enfurtide-based antiretroviral therapy. AIDS 2003;17:691-698.
    5. Lalezari J, DeJesus E, Northfelt D, Richmond, Wolfe P, Haubrich R, Henry D, Powderly W, Becker S, Thompson M, Valentine F, Wright D, Carlson M, Riddler S, Haas F, DeMasi R, Sista P, Salgo M, Delehanty J. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naïve HIV-infected adults. Antiviral Therapy, 2003:8(4) 279-287.
    6. Gulick, Roy et al for the AIDS Clinical Trials Group Study A5095 Team. Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the initial Treatment of HIV-1 Infection. NEJM 2004; 350:1850-61.
    7. Gulick; Roy; Ribaudo H; Shikuma, C; Lalama, C; Schackman,B ; Meyer, W; Acosta,E; Schouten,J;Squires, K; Pilcher, C; Murphy.R; Koletar, S; Carlson, M; Reichman, R; Bastow, B; Klingman, K; Kuritzkes, D; for the AIDS Clinical Trials Group (ACTG) A5095 Study Team Three- vs Four-Drug Antiretroviral Regimens for the Initial Treatment of HIV-1 Infection: A Randomized Controlled Trial JAMA. 2006;296:769-781.

    Link to my pubmed publications »